Publications

  • Betzaida Castillo Cruz , Sandra Chinapen Barletta , Bryan G Ortiz Muñoz , Adriana S Benitez-Reyes, Omar A Amalbert Perez, Alexander C Cardona Amador, Pablo E Vivas-Mejia, Gabriel L Barletta. Effect of Cyclodextrins Formulated in Liposomes and Gold and Selenium Nanoparticles on siRNA Stability in Cell Culture Medium PMID: 39458985 PMCID: PMC11510567 DOI: 10.3390/ph17101344
  • Estupiñan-Jiménez JR, Villarreal-García V, Gonzalez-Villasana V, Vivas-Mejia PE, Vazquez-Guillen JM, Zapata-Morin PA, Flores-Colón M, Altamirano-Torres C, Viveros-Valdez E, Ivan C, Rashed MH, Bayraktar R, Rodríguez-Padilla C, Lopez-Berestein G, Resendez-Perez D. MicroRNA-1307-3p contributes to breast cancer progression through PRM2. Thorac Cancer. 2024 Oct 9. doi: 10.1111/1759-7714.15460. Epub ahead of print. PMID: 39382427.
  • Castillo Cruz, B.; Chinapen Barletta, S.; Ortiz Muñoz, B.G.; Benitez-Reyes, A.S.; Amalbert Perez, O.A.; Cardona Amador, A.C.; Vivas-Mejia, P.E.; Barletta, G.L. Effect of Cyclodextrins Formulated in Liposomes and Gold and Selenium Nanoparticles on siRNA Stability in Cell Culture Medium. Pharmaceuticals 2024, 17, 1344. https://doi.org/10.3390/ph17101344.
  • Flores-Colón M, Rivera-Serrano M, Reyes-Burgos VG, Rolón JG, Pérez-Santiago J, Marcos-Martínez MJ, Valiyeva F, Vivas-Mejía PE. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer. Int J Mol Sci. 2024 Mar 28;25(7):3793. doi: 10.3390/ijms25073793. PMID: 38612604; PMCID: PMC11011404.
  • Velázquez-Vega LE, Rivera-Robles M, Sánchez-Álvarez AO, Vivas-Mejía PE, Aponte-Reyes M, Cruz-Collazo AM, Grafals-Ruiz N, Dorta-Estremera S, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer. S.Transl Oncol. 2024 Jun;44:101928. doi: 10.1016/j.tranon.2024.101928. Epub 2024 Mar 15. PMID: 38489873
  • Grafals-Ruiz N, Sánchez-Álvarez AO, Santana-Rivera Y, Lozada-Delgado EL, Rabelo-Fernandez RJ, Rios-Vicil CI, Valiyeva F, Vivas-Mejia PE. MicroRNA-92b targets tumor suppressor gene FBXW7 in glioblastoma. Front Oncol. 2023 Sep 11;13:1249649. doi: 10.3389/fonc.2023.1249649. PMID: 37752997; PMCID: PMC10518455.
  • Rabelo-Fernández, R.J.; Noriega Rivera, R.A.; Rivera, Y.S.; Tous-Beveraggi, J.; Valiyeva, F.; Vivas-Mejia, P.E. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells. Int. J. Mol. Sci. 2022, 23, 14742. https://doi.org/10.3390/ijms232314742.
  • Villarreal-García V, Estupiñan-Jiménez JR, Vivas-Mejía PE*, Gonzalez-Villasana V*, Vázquez-Guillén JM, Reséndez-Pérez D. A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. Front. Oncol., 26 September 2022; Sec. Breast Cancer; https://doi.org/10.3389/fonc.2022.980694.
  • Noriega-Rivera R, Rivera-Serrano M, Rabelo-Fernandez RJ, Pérez-Santiago J, Valiyeva F, Vivas-Mejía PE. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer. Int. J. Mol. Sci. 2022, 23, 7737.
  • Castillo-Cruz B, Flores Colon M, Rabelo Fernendez, RJ, Vivas-Mejia, PE and Barletta, GL. A Fresh Look at the Potential of Cyclodextrins for Improving the Delivery of siRNA Encapsulated in Liposome Nanocarriers. ACS Omega, 2022. DOI: 10.1021/acsomega.1c06436.
  • Rabelo-Fernández RJ, Santiago-Sánchez GS, Sharma RK, Roche-Lima A, Carrion KC, Rivera RAN, Quiñones-Díaz BI, Rajasekaran S, Siddiqui J, Miles W, Rivera YS, Valiyeva F, Vivas-Mejia PE. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells. Int. J. Mol. Sci. 2022; 23(1):535. https://doi.org/10.3390/ijms2301053.
  • Santiago-Sánchez, G.S.; Noriega-Rivera, R.; Hernández-O’Farrill, E.; Valiyeva, F.; Quiñones-Diaz, B.; Villodre, E.S.; Debeb, B.G.; Rosado-Albacarys, A.; Vivas-Mejía, P.E. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. Int. J. Mol. Sci. 2021, 22, 8581. https://doi.org/10.3390/ijms22168581.
  • Sharma, RK, Calderon, C and Pablo E. Vivas-Mejia, PE. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. Front. Med. Technol., 10 August 2021 | https://doi.org/10.3389/fmedt.2021.678593.
  • Emilly S. Villodre, Xiaoding Hu, Richard Larson, Pascal Finetti, Kristen Gomez, Wintana Balema, Shane R. Stecklein, Ginette Santiago-Sanchez, Savitri Krishnamurthy, Juhee Song, Xiaoping Su, Naoto T. Ueno, Debu Tripathy, Steven Van Laere, Francois Bertucci, Pablo Vivas-Mejía, Wendy A. Woodward, Bisrat G. Debeb. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. bioRxiv 2021.03.18.436052; doi: https://doi.org/10.1101/2021.03.18.436052.
  • Quiñones-Díaz BI, Reyes-González JM, Sánchez-Guzmán V, Conde-Del Moral I, Valiyeva, F, Santiago-Sánchez GS, and Pablo E. Vivas-Mejía PE. MicroRNA-18a-5p Suppresses Tumor Growth via Targeting Matrix Metalloproteinase-3 in Cisplatin-Resistant Ovarian Cancer. Front. Oncol., 17 December 2020; PMID: 33392094 PMCID: PMC7774672 DOI: 10.3389/fonc.2020.602670.
  • Grafals-Ruiz N, Rios-Vicil CI, Lozada-Delgado EL, Quiñones-Díaz BI, Noriega-Rivera RA, Martínez-Zayas G, Santana-Rivera Y, Santiago-Sánchez GS, Valiyeva F, Vivas-Mejía PE. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma. Int J Nanomedicine. 2020;15:2809-2828; ttps://doi.org/10.2147/IJN.S241055.
  • Reyes-González, J.M.; Quiñones-Díaz, B.I.; Santana, Y.; Báez-Vega, P.M.; Soto, D.; Valiyeva, F.; Marcos-Martínez, M.J.; Fernández-de Thomas, R.J.; Vivas-Mejía, P.E. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer. Cancers 2020, 12, 880.
  • Santana-Rivera Y, Rabelo-Fernández RJ, Quiñones-Díaz BI, Grafals-Ruíz N, Santiago-Sánchez G, Lozada-Delgado EL, Echevarría-Vargas IM, Apiz J, Soto D, Rosado A, Meléndez L, Valiyeva F, Vivas-Mejía PE. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells. Am J Transl Res. 2020 Apr 15;12(4):1275-1292. PMID: 32355541; PMCID: PMC7191177.
  • Mendez, B.; Reyes, J.; Conde, I.; Ramos, Z.; Lozada, E.; Cruz, A.M.; Asencio, G.; Carvajal, A.; Dharmawardhane, S.; Piñero-Cruz, D.M.; Hernández, E.; Vivas, P.; Ospina, C.A. Simalikalactone D, a Potential Anticancer Compound from Simarouba tulae, an Endemic Plant of Puerto Rico. Plants 2020, 9, 93.
  • Lozada-Delgado EL, Grafals-Ruiz N, Miranda-Román MA, Santana-Rivera Y, Valiyeva F, Rivera-Díaz M, Marcos-Martínez MJ, Vivas-Mejía PE. Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression. Cancers (Basel). 2018 Oct 12;10(10). pii: E382. doi: 10.3390/cancers10100382. PMID: 30322013 PMCID: PMC6210372
  • Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sci. 2017 Nov 1;188:26-36. PMID: 28864225.
  • Perla Baez, Ileabett Echevarria, Adriana Roman, Josean Flores, Fatma Valiyeva, Maria Marcos and Pablo E. Vivas-Mejia. Targeting miR-21-3p Inhibits Proliferation and Invasion of Ovarian Cancer Cells. Oncotarget. June 14, 2016, PMID: 27166999 PMCID: PMC5095003.
  • Alcedo-Guardia, R., Labat, E., Blas-Boria, D., & Vivas-Mejia, P. E. (2016). Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival? Curr Mol Med, 16. PMID: 26585986. Review article.
  • Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 9;28(5):610-22. doi: 10.1016/j.ccell.2015.09.008. Epub 2015 Oct 17. PMID:26481148.
  • Reyes-González JM, Armaiz-Pena GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejia PE. Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther. 2015 Jul 30. pii: molcanther.0801.2014. PMID: 26227489.
  • Jeyshka Reyes, Frances Pietri and Pablo E. Vivas-Mejia, A general overview of nanocarriers for drug delivery. Book Chapter. For invitation: Nano Based Drug Delivery IAPC-OBP Editors;2015, ISBN: 978-953-56942-2-9.
  • Rivera-Diaz, M, Miranda-Roman, M, Soto, D, Quintero-Aguilo, M, Ortiz-Zuazaga, H, Marcos-Martinez, MJ, and Vivas-Mejía, PE. MicroRNA-27a Distinguishes Glioblastoma Multiforme from Diffuse and Anaplastic Astrocytomas and Has Prognostic Value. PMID:25628931; PMCID: PMC4300691. 2015: 5(1); 201-218.
  • Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15;21(2):448-59. doi: 10.1158/1078-0432.CCR-14-1578.
  • Echevarría Vargas, IM., Valiyeva, F., and Vivas-Mejía, PE. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLosOne. 2014; 9: e97094. doi:10.1371/journal.pone.0097094. PMID:24865582; PMCID: PMC4035252.
  • Diaz, MR, Vivas-Mejia, PE. Nanoparticles as drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-containing Nanoliposomes. Review article. Pharmaceuticals 2013, 6, 1362-1380.
  • Echevarria-Vargas, IM., and Vivas-Mejía, PE., Assessment of mRNA Splice Variants by qRT-PCR. Book Chapter: Humana Press series "Methods in Molecular Biology", 2013 . ISBN 978-1-62703-546-0
  • Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.  Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.  Nat Commun. 2013 Jan 29;4:1403. doi: 10.1038/ncomms2413. PMID:23360994.
  • Moreno-Smith, M, Halder, J.B., Meltzer, P., Gonda, T., Mangala, L., Vivas-Mejia, PE., Zand, B., Schmandt, R., Hua Wang, H., Langley, R., Jennings, NB., Ivan, C., Coffin, J., Armaiz-Pena, GN., Bottsford-Miller, J., Pecot, C., Kim, SB., Halleck, M., Hendrix, MJC., Menashe Bar-Eli, M., Lee, MJS., Siddik, Z., Lopez-Berestein, G., and Sood, AK. Unexpected roles of ATP11B in platinum resistance. JCI.  2013. DOI:10.1172/JCI65425.
  • Vivas-Mejia, PE*, Rodriguez-Aguayo, C., Han, HD., Shahzad, MMK., Valiyeva, F., Shibayama, M., Chavez-Reyes, A., Sood, AK., and Lopez-Berestein, G*. Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer. Clin Cancer Res. 2011 June 1; 17(11): 3716-3726. Published online 2011 April 21. doi:  10.1158/1078-0432.CCR-11-0233, *Corresponding authors.
  • Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekederli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK.  Silencing of p130cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death.  J Natl Cancer Inst. 2011. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.
  • Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G,  Sood AK, and Vadlamudi, RK Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clinical Cancer Research, March 2011. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18.
  • Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology. 2011 Nov;141(5):1728-37. Epub 2011 Jul 30.
  • Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011;6(7):e21121. Epub 2011 Jul 6.PMID: 21754983.
  • Sood, AK., Armaiz-Pena, GN., Halder, J., Nick, AM., Stone, RL., Wei Hu, W., Carroll, AR., Spannuth, WA., Deavers, MT., Allen, JK., Han, LY., Kamat, AA., Shahzad, AMK., McIntyre, BW., Diaz-Montero, CM., Jennings, NB., Lin, YG., Merritt, WM., DeGeest, K., Vivas-Mejia, PE., Lopez-Berestein, G.,. Schaller, MD., Cole, SW., and Lutgendorf, SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010. doi:10.1172/JCI40802.
  • Tanaka, T., Mangala, LS., Vivas-Mejia, PE., Nieves, RA., Mann, AP., Mora, E., Han, HD., Shahzad, MMK., Lu, XC., Bhavane, R., Gu, J., Fakhoury, J., Chiappini, C., Godin-Vilentchouk, B., Stone, RL., Nick, AM., Lopez-Berestein, G., Sood, AK., and Ferrari, M. Sustained siRNA Delivery by Mesoporous Silicon Particles for Cancer Treatment. Cancer Res. 2010 May 1; 70(9):3687-96.
  • Mian M. K. Shahzad, Jesusa M. Arevalo, Guillermo N. Armaiz-Pena, Chunhua Lu, Rebecca L. Stone, Myrthala Moreno-Smith, Masato Nishimura, Jeong-Won Lee, Nicholas B. Jennings, Justin Bottsford-Miller, Pablo Vivas-Mejia, Susan K. Lutgendorf, Gabriel Lopez-Berestein, Menashe Bar-Eli, Steven W. Cole and Anil K. Sood. Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis. J Biol Chem  285: 35462 (2010) PMID 20826776.
  • Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Vivas-Mejia, PE, Jennings NB, Gershenson DM, Bast RC, Jr., Coleman RL, Berestein G, and Sood AK.  Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Can Ther, 2010 (12):3186-99.
  • Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma. Mol Cancer Ther. 2010 Aug;9(8):2377-88.
  • Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 285(46):35462-70.
  • Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF; Australian Ovarian Cancer Study Group, Vivas-Mejia PE, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC Jr. SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer. Cancer Cell. 2010 Aug 9;18(2):109-121.
  • Vivas-Mejia, PE., Benito, JM., Fernandez, A., Han, HD., Mangala, L., Rodriguez-Aguayo, C., Lin, YG., Nick, AM., Stone, RL., Kim, HS., Claret, FX, Bornmann, W., Hennessy, BTJ., Peng, Z., Sood, AK., and Lopez-Berestein, G. JNK-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-09-1180. Epub 2009 Dec 22.
  • Vivas-Mejía PE. Ozpolant B, Chen X and Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to Arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.  International Journal of Cancer. Volume 125, Issue 2, Date: 15 July 2009, Pages: 264-275.
  • Mian M.K. Shahzad , Chunhua Lu, Jeong-Won Lee, Rebecca L. Stone, Rahul Mitra, Lingegowda S. Mangala, Yiling Lu, Keith A. Baggerly, Christopher G. Danes, Alpa M. Nick, Jyotsnabaran Halder, Hye-Sun Kim, Pablo Vivas-Mejia, Charles N Landen, Gabriel Lopez-Berestein, Robert L Coleman, Anil K. Sood. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biology & Therapy, June 1, 2009: 8 (11).
  • Mangala, LS., Zuzel, V., Schmandt, R., Leshane, ES., Halder, JB., Armaiz-Pena, GN., Spannuth, WA., Tanaka, T., Shahzad, MMK., Lin, YG., Nick, AM., Danes, CG., Lee,JW., Jennings, NB., Vivas-Mejia, PE., Wolf, JK., Coleman, RL., Siddik, ZH., Lopez-Berestein, G., Lutsenko, S., and Sood, AK. Therapeutic targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 1;15(11):3770-80.
  • Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE,  Deavers MT, ColemanRL, Lopez-Berestein G, Mehta K, and Sood AK. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Res., Jul 2008; 68: 5849 - 5858.
  • Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene, Sep 22, 2008.
  • Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia PE, Acevedo-Alvarez M, and Lopez-Berestein  G.  Death-Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia. Apoptosis: an international journal on programmed cell death. 2008;13 (7):915-28.
  • Naguib, MP., Diaz, J.,  Xu, JF.,  Astruc-Diaz, F., Craig, S., P Vivas-Mejia. PE., and D L Brown, DL., MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. British Journal of Pharmacology, September 2008; doi: 10.1038/bjp.2008.340.
  • Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Michael C. Leslie MC,  Vivas-Mejia PE, Lopez-Berestein G, Sood AK, and Bar-Eli M. Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA. Cancer Res., Nov 2008; 68: 9078 - 9086.
  • Robles, Y, Vivas-Mejía PE, Ortiz-Zuazaga, HG, Félix Y, Ramos X, and Peña de Ortiz S. Hippocampal gene expression profiling in spatial discrimination learning. Neurobiology of Learning & Memory; 2003: 2-80 (80-95).
  • Gendron FP, Newbold NL, Vivas-Mejía PE, Wang M, Neary JT, Sun GY, Gonzalez FA, and Weisman, GA. Signal transduction pathways for P2Y2 and P2X7 nucleotide receptors that mediate neuroinflamatory responses in astrocytes and microglial cells. Biomedical Research; 2003: 14(1): 50-67.
  • Weisman GA, Griffin K, Santiago-Perez, LI, Liu, J, Krugh B, Flores, RV, Crorna RN, C. Santos-Berrios C, Vivas-Mejia PE, Garrad RC, Gonzalez FA, and Erb L. P2Y2 receptors regulate multiple signal transduction pathways in monocytic cells. Drug Dev. Res. 2001: 53.
  • Lozano CM, Cox O, Vivas-Mejía PE., Muir MM, Morales JD, Rodríguez-Caban JL, and González FA. Cytotoxic Aionic Tribromo Platinium (II) Complex Containing Benzothiazole and Benzaxole Donors. Inorganica Chemica Acta; 1998: 271: 137-144.
  • Vivas-Mejía PE, Cox O, and González FA. Inhibition of Human Topoisomerase II by Benzazolo [3,2-a] quinolinium Chlorides: Molecular basis of Drug Action. Molecular and Cellular Biochemistry; 1998: 178: 203-212.
  • Vivas-Mejía PE, Rodríguez-Caban JL, Velázquez M, Hernandez-Perez, M, Cox O, González FA. DNA Binding-independent Anti-proliferative Action of Benzazolo [3,2-a] quinolinium DNA intercalators. Molecular and Cellular Biochemistry; 1997: 178: 67-77.